

# Validation of mild cognitive impairment in Parkinson's disease

<https://neurodegenerationresearch.eu/survey/validation-of-mild-cognitive-impairment-in-parkinsons-disease/>

## Principal Investigators

dr. G.J. Geurtsen

## Institution

AMC

## Contact information of lead PI

### Country

Netherlands

## Title of project or programme

Validation of mild cognitive impairment in Parkinson's disease

## Source of funding information

Parkinson Vereniging

## Total sum awarded (Euro)

€ 68,338

## Start date of award

01/01/2014

## Total duration of award in years

2

## Keywords

Research Abstract

This project aims to validate the MDS PD-MCI criteria by pooling and analyzing cross-sectional and longitudinal neuropsychological databases comprising ?5,500 PD patients and ?1,700 controls. After applying the MDS PD-MCI Level I and Level II criteria, rates of conversion to PD-dementia and predictive variables for conversion to PD-dementia will be established. This study will also assist in identifying whether revisions of the PD-MCI criteria are required. Goals 1. Validation of the MDS PD-MCI criteria comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to detect PD-MCI and predict conversion to dementia applicability of the criteria. 2. Definition of best cut-off score to discriminate patient with and without PD-MCI to predict conversion to dementia

3. Generating epidemiologic data by:

defining the prevalence of PD-MCI  
comparing the prevalence across different sites/cohort types  
defining the prevalence of the different subtypes of PD-MCI

4. Determine relationship PD-MCI, mood and Quality of Life analyzing mood and Quality of Life in no-PD-MCI, PD-MCI and PDD groups

#### Additional Information

The 24 international sites have PD cohorts that are being combined. These cohorts include ? 3,600 PD patients and ? 1,500 controls to validate level I in ? 2,100 patients whom 82% participate in longitudinal studies and ? 1,500 patients to validate level II. Just over 640 (43%) of those level II patients are followed longitudinally. Two PhD student have started October 2013 and the planned duration of the validation project is two years.

#### Further information available at:

<http://www.movementdisorders.org/MDS/About/Committees--Other-Groups/Study-Groups/Validation-of-Mild-Cognitive-Impairment-in-Parkinson-Disease-MCI-Study-Group.htm>

#### Types:

Investments < €500k

#### Member States:

Netherlands

#### Diseases:

N/A

#### Years:

2016

#### Database Categories:

N/A

#### Database Tags:

N/A